ALAR PHARMACEUTICALS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 262 TWD | +0.77% |
|
-8.07% | +25.06% |
| Sales 2022 | 800K 24.69K | Sales 2023 | 469M 14.48M | Capitalization | 11.94B 369M |
|---|---|---|---|---|---|
| Net income 2022 | -19M -586K | Net income 2023 | 383M 11.82M | EV / Sales 2022 | 7,589 x |
| Net cash position 2022 | 484M 14.92M | Net cash position 2023 | 895M 27.61M | EV / Sales 2023 | 23.5 x |
| P/E ratio 2022 |
-330
x | P/E ratio 2023 |
31.2
x | Employees | 22 |
| Yield 2022 * |
-
| Yield 2023 |
0.72% | Free-Float | 54.71% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.77% | ||
| 1 week | -8.07% | ||
| Current month | -8.07% | ||
| 1 month | -2.24% | ||
| 3 months | -20.00% | ||
| 6 months | +37.17% | ||
| Current year | +25.06% |
1 week
259.50
285.50
1 month
240.50296.50
Current year
194.00465.00
1 year
116.00465.00
3 years
42.80465.00
5 years
42.80465.00
10 years
42.80465.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yung Shun Wen
CEO | Chief Executive Officer | - | 16-09-22 |
Vivian Kang
DFI | Director of Finance/CFO | - | 19-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Lin
CHM | Chairman | - | 16-09-22 |
Yung Shun Wen
CEO | Chief Executive Officer | - | 16-09-22 |
Cheng Yu Fang
BRD | Director/Board Member | - | 18-08-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 262 | +0.77% | 310,986 |
| 24-06-06 | 260 | -4.06% | 415,771 |
| 24-06-05 | 271 | -0.91% | 195,376 |
| 24-06-04 | 273.5 | -0.91% | 188,308 |
| 24-06-03 | 276 | -3.16% | 325,646 |
End-of-day quote Taipei Exchange, June 06, 2024
More quotes
Alar Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The Company mainly develops long-acting drugs for the treatment of opioid use disorder, treatment-resistant depression, and Parkinson disease. The main products include ALA-1000, buprenorphine subcutaneous long-acting sustained-release injection, is indicated for indicated for opioid use disorder (OUD); ALA-1300, subcutaneous injection, is indicated for opioid addiction; ALA-3000, ketamine subcutaneous long-acting sustained-release injection, is indicated for treatment-resistant depression (TRD); ALA-4000, apomorphine subcutaneous long-acting sustained-release injection, is indicated for Parkinson disease (PD); and ALA-2000, subcutaneous injection, is indicated for alcohol addiction and opioid use disorder. The Company distributes ALA-1000 and related products to the United States, France, Germany, the United Kingdom, Italy, and Japan markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +25.06% | 540M | |
| +18.88% | 80.5B | |
| +14.11% | 9.15B | |
| -14.14% | 4.9B | |
| +43.39% | 4.49B | |
| +18.90% | 4.44B | |
| +7.93% | 2.19B | |
| -28.40% | 2.13B | |
| +15.93% | 2.1B | |
| -43.17% | 1.78B |
- Stock Market
- Equities
- 6785 Stock
